INVESTOR RELATIONS
Isofol resolves on a fully guaranteed Rights Issue
May 12, 2025
“We are very pleased to announce a fully guaranteed rights issue, under terms favourable to the company, which secures the financing for our expanded Phase II study – an important step towards realising our long-term vision. We are also proud that so many of our major existing shareholders have chosen to commit to subscription undertakings, and that our partner Solasia has undertaken to subscribe for units in the issue, confirming the confidence in our strategy and the belief in the potential of arfolitixorin,” says CEO, Petter Segelman Lindqvist.
Listen to the inteview with CEO, Petter Segelman Lindqvist made by Redeye (in Swedish).
INVESTORS – latest reports and presentations
Media – Lates pressreleases
Interview with Isofol’s CEO Petter Segelman Lindqvist on upcoming rights issue
GOTHENBURG, Sweden, May 14, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company’s CEO Petter Segelman Lindqvist has been…
Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, May 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) has today…
SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS
About arfolitixorin
Want to know more about the the drug candidate arfolitxorin?
Last updated 05-13-2025
